Key points:
- I would expect Johnson & Johnson to see something similar.
- Large Pharma’ and biotech companies have invested extensively in research and development and in improving production during the pandemic.
- Hopefully, by next year, we will probably have 10 vaccinations that have proved their worth.
- Cueni said the IFPMA archives revealed that a compulsory license for the vaccine had never been issued.
If they gain regulatory approval, ten Covid-19 vaccines may be accessible by the middle of next year, but their inventors require patent protection, the leader of the global pharmaceutical industry group stated on Friday.
Director-General of (IFPMA) Thomas Cueni stated:
In major clinical trials, Pfizer and BioNtech vaccines, as well as Moderna and AstraZeneca have shown impressive results, but there is no issue of “cutting corners,” said Thomas Cueni, Director-General of the International Federation of Pharmaceutical Producers and Associations
(IFPMA).
“We’ve got 3 out of 3 hits so far. I would expect Johnson & Johnson to see something similar, I would expect Novavax to see similar promising results, as well as many more, Sanofi Pasteur, GSK is there, Merck,’ he said.
Cueni told during Geneva news conference:
In order to be able to roll out vaccine doses, ‘Large Pharma’ and biotech companies have invested extensively in research and development and in improving production during the pandemic, Cueni told a Geneva news conference.
Without expert personnel and quality management procedures, that this would be a mistake to raise patent protection to allow compulsory licensing and attempt to make vaccines requiring such complicated quality assurance, he said.
10 vaccines till next year:
Hopefully, by next year, we will probably have 10 vaccinations that have proved their worth. But all of them really need to be sent to regulators through thorough scientific review.
As a trade official stated:
India as well as South Africa has proposed to the World Trade Organization (WTO) to allow a temporary waiver to permit compulsory licensing during the pandemic for proprietary goods.
It has been rejected by the United States, the European Union, and Switzerland, as well as others, trade officials say.
IP questioning is primarily politics to me Cueni stated:
Questioned about the proposal, Cueni said That this IP questioning is really primarily politics to me, but it is politics that is not useful because it would send very negative signals in terms of disrespect for the system that allowed the world to respond so quickly and so responsibly.”
Vaccine manufacturing plants also need 50 quality assurance workers to carry out hundreds of production controls, he said, stressing that the companies will not exploit this pandemic.
Cueni on license for vaccine:
Cueni said the IFPMA archives revealed that a compulsory license for a vaccine had never been issued and pointed to challenging technology and know-how. During the pandemic, he said, almost every member organization had committed to not-for-profit’ either socially responsible pricing.
